Bispecific-antibody therapy (BAT), the next strategy of immunotherapy for tumor patients, has showed the enhanced antitumor benefits than the monotherapy. Yet, few effective biomarkers were developed to monitor the response. Here, we investigated the first BAT longitudinal plasma proteome profiling ...
ORGANISM(S): Homo Sapiens
